Evidence map›Paper›PMID 32880812›Full record

ArticleClinical journal of gastroenterology2020

Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.

Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama and 7 more

Erratum issuedAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Yoshinori AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan. yoshinori.a1@gmail.com.ORCID http://orcid.org/0000-0002-0726-3474
Maiko OgawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Fumitsugu YamaneDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Natsuki SumiyoshiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Rikako ArimotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Yoshitaka AndoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Daisuke EndoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Tatsuya NakadaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Ichiro SugawaraDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Hiroshi YokoyamaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Keiko ShimoyamaDepartment of Endoscopy, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Hiroko InomataDepartment of Endoscopy, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Yosuke KawaharaDepartment of Endoscopy, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Masayuki KatoDepartment of Endoscopy, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Seiji ArihiroDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Atsushi HokariDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan.
Masayuki SarutaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesalazine formulations are essential for treating ulcerative colitis (UC), and intolerance to these formulations complicates the treatment of this condition. Some cases of mesalazine formulation intolerance are caused by the excipients rather than the active ingredient mesalazine. Therefore, mesalazine administration can be continued in such cases by changing the mesalazine formulation. This report describes a case of intolerance to mesalazine in which UC was effectively treated by switching mesalazine formulations. A drug-induced lymphocyte stimulation test suggested that allergy to the additive povidone was the cause of mesalazine formulation intolerance. This is the first case study to identify an additive that caused mesalazine formulation intolerance.

Indexed as

Colitis, UlcerativeHypersensitivityAnti-Inflammatory Agents, Non-SteroidalExcipientsHumansMesalamineAnti-Inflammatory Agents, Non-SteroidalExcipientsMesalamineDrug-induced lymphocyte stimulation testExcipientMesalazine formulation intoleranceUlcerative colitis

Identifiers

PMID32880812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.